Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Spencer Dreher

Norihiro Ikemoto

Yong Zhang

Subharekha Raghavan

Jian Guo

Alan Whitehead

J Michael Williams

Jonathan A Groeper

Xiaoqing Han

Timothy A Cernak

C Scott Shultz

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof. 

Soluble guanylate cyclase activators

This invention relates to a process for preparing optically active &#x3b1;-amino acid substrates which are used to make potent lethal factor (LF) inhibitors for the treatment of anthrax. This invention further relates to a process for synthesis of potent LF-inhibitors for the treatment of anthrax. Specifically, the invention concerns a novel, high-yielding and highly enantioselective asymmetric hydrogenation reaction of a tetrasubstituted ene-sulfonamide acid or ester.

Process for making N-sulfonated-amino acid derivatives

The present invention is concerned with a process for the preparation of trifluorophenylacetic acids using a Grignard reagent and an allylating agent, such as allyl bromide.

Process for the synthesis of trifluorophenylacetic acids

Growing community of inventors

Metuchen, NJ, United States of America

Spencer Dreher